SAB Biotherapeutics, Inc.
SABS
$3.72
$0.082.20%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.70K | 114.70K | 377.80K | 1.32M | 1.51M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.70K | 114.70K | 377.80K | 1.32M | 1.51M |
| Cost of Revenue | 8.82M | 8.81M | 22.61M | 23.10M | 19.75M |
| Gross Profit | -8.71M | -8.70M | -22.24M | -21.78M | -18.24M |
| SG&A Expenses | 12.03M | 11.80M | 12.71M | 13.78M | 26.19M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.31M | 41.94M | 42.67M | 44.23M | 53.29M |
| Operating Income | -43.19M | -41.82M | -42.29M | -42.91M | -51.78M |
| Income Before Tax | 18.74M | -37.06M | -34.28M | -34.11M | -45.57M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 18.74 | -37.06 | -34.28 | -34.11 | -45.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.74M | -37.06M | -34.28M | -34.11M | -45.57M |
| EBIT | -43.19M | -41.82M | -42.29M | -42.91M | -51.78M |
| EBITDA | -40.09M | -38.52M | -38.71M | -38.12M | -46.82M |
| EPS Basic | -0.54 | -2.15 | -3.70 | -3.68 | -5.84 |
| Normalized Basic EPS | 0.87 | -2.50 | -2.31 | -2.30 | -3.65 |
| EPS Diluted | -1.25 | -2.16 | -3.70 | -3.68 | -5.84 |
| Normalized Diluted EPS | -1.43 | -2.50 | -2.31 | -2.30 | -3.65 |
| Average Basic Shares Outstanding | 38.54M | 37.14M | 37.10M | 37.05M | 34.52M |
| Average Diluted Shares Outstanding | 105.75M | 37.14M | 37.10M | 37.05M | 34.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |